The complaint filed against the firm asserts that Erasca issued materially false statements concerning its preclinical data for ERAS-0015. Specifically, the litigation alleges that the company relied on improper comparisons to Revolution Medicines, Inc., potentially infringing on trade secret and patent protections. These omissions, according to the filing, deprived investors of a reasonable basis for the company's positive projections during the class period.
In section Releases
Erasca Investors Face August Deadline in Securities Litigation
Investors who purchased Erasca, Inc. stock between January 14, 2025, and April 26, 2026, have until August 10, 2026, to file as lead plaintiffs in a pending class action lawsuit. The case centers on allegations that the company misled shareholders regarding the development of its ERAS-0015 drug candidate.
The Gross Law Firm is managing the registration process for those seeking to participate in the recovery effort. Shareholders who register their information will be enrolled in portfolio monitoring to receive updates throughout the case. Participation as a lead plaintiff is optional, and there is no cost or obligation associated with joining the class action.
Comments (0)
No comments yet. Be the first!